Many in vitro and in vivo studies have been performed on JQ1, a competitive interactor of BRD2 and BRD4 acetyl-lysine binding motifs, to assess its antitumor effects in various B-NHL [21, 25, 65–69] (i.e., DLBCL, BL, MCL) and some virus-associated lymphomas, including Kaposi's sarcoma-associated herpes virus (KSHV) positive pleural effusion lymphoma (PEL) [70], and EBV positive BL [71]. Here, BRD4 is linked to Burkitt lymphoma.